These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25394171)

  • 1. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.
    Bennette CS; Gallego CJ; Burke W; Jarvik GP; Veenstra DL
    Genet Med; 2015 Jul; 17(7):587-95. PubMed ID: 25394171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.
    Gallego CJ; Shirts BH; Bennette CS; Guzauskas G; Amendola LM; Horike-Pyne M; Hisama FM; Pritchard CC; Grady WM; Burke W; Jarvik GP; Veenstra DL
    J Clin Oncol; 2015 Jun; 33(18):2084-91. PubMed ID: 25940718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review of the Economic Evaluation of Returning Incidental Findings in Genomic Research.
    Fontes Marx M; Ataguba JE; de Vries J; Wonkam A
    Front Public Health; 2021; 9():697381. PubMed ID: 34277554
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.
    Gallego CJ; Bennette CS; Heagerty P; Comstock B; Horike-Pyne M; Hisama F; Amendola LM; Bennett RL; Dorschner MO; Tarczy-Hornoch P; Grady WM; Fullerton SM; Trinidad SB; Regier DA; Nickerson DA; Burke W; Patrick DL; Jarvik GP; Veenstra DL
    Contemp Clin Trials; 2014 Sep; 39(1):1-8. PubMed ID: 24997220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Return of non-ACMG recommended incidental genetic findings to pediatric patients: considerations and opportunities from experiences in genomic sequencing.
    Bowling KM; Thompson ML; Kelly MA; Scollon S; Slavotinek AM; Powell BC; Kirmse BM; Hendon LG; Brothers KB; Korf BR; Cooper GM; Greally JM; Hurst ACE
    Genome Med; 2022 Nov; 14(1):131. PubMed ID: 36414972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings.
    Phillips KA; Ladabaum U; Pletcher MJ; Marshall DA; Douglas MP
    Genet Med; 2015 Apr; 17(4):314-5. PubMed ID: 25835195
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.
    Li Y; Bare LA; Bender RA; Sninsky JJ; Wilson LS; Devlin JJ; Waldman FM
    Mol Diagn Ther; 2015 Jun; 19(3):169-77. PubMed ID: 25926090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analyses of genetic and genomic diagnostic tests.
    Payne K; Gavan SP; Wright SJ; Thompson AJ
    Nat Rev Genet; 2018 Apr; 19(4):235-246. PubMed ID: 29353875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Sequencing vs Culture-Based Methods for Diagnosing Periprosthetic Joint Infection After Total Knee Arthroplasty: A Cost-Effectiveness Analysis.
    Torchia MT; Austin DC; Kunkel ST; Dwyer KW; Moschetti WE
    J Arthroplasty; 2019 Jul; 34(7):1333-1341. PubMed ID: 31005439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).
    Rehder C; Bean LJH; Bick D; Chao E; Chung W; Das S; O'Daniel J; Rehm H; Shashi V; Vincent LM;
    Genet Med; 2021 Aug; 23(8):1399-1415. PubMed ID: 33927380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Intracranial Aneurysms in Coarctation of the Aorta: A Decision and Cost-Effectiveness Analysis.
    Pickard SS; Prakash A; Newburger JW; Malek AM; Wong JB
    Circ Cardiovasc Qual Outcomes; 2020 Aug; 13(8):e006406. PubMed ID: 32762482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding Radical Surgery in Elderly Patients With Rectal Cancer Is Cost-Effective.
    Rao C; Sun Myint A; Athanasiou T; Faiz O; Martin AP; Collins B; Smith FM
    Dis Colon Rectum; 2017 Jan; 60(1):30-42. PubMed ID: 27926555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.
    Cohen DJ; Breall JA; Ho KK; Kuntz RE; Goldman L; Baim DS; Weinstein MC
    Circulation; 1994 Apr; 89(4):1859-74. PubMed ID: 8149551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study.
    Hart MR; Biesecker BB; Blout CL; Christensen KD; Amendola LM; Bergstrom KL; Biswas S; Bowling KM; Brothers KB; Conlin LK; Cooper GM; Dulik MC; East KM; Everett JN; Finnila CR; Ghazani AA; Gilmore MJ; Goddard KAB; Jarvik GP; Johnston JJ; Kauffman TL; Kelley WV; Krier JB; Lewis KL; McGuire AL; McMullen C; Ou J; Plon SE; Rehm HL; Richards CS; Romasko EJ; Miren Sagardia A; Spinner NB; Thompson ML; Turbitt E; Vassy JL; Wilfond BS; Veenstra DL; Berg JS; Green RC; Biesecker LG; Hindorff LA
    Genet Med; 2019 May; 21(5):1100-1110. PubMed ID: 30287922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consideration for Employer-Based and Geographic Attributes Included in Value Assessment Methods of Next-Generation Sequencing Tests.
    Hart MR; Spencer SJ
    J Manag Care Spec Pharm; 2019 Aug; 25(8):936-940. PubMed ID: 31347979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.
    Amendola LM; Jarvik GP; Leo MC; McLaughlin HM; Akkari Y; Amaral MD; Berg JS; Biswas S; Bowling KM; Conlin LK; Cooper GM; Dorschner MO; Dulik MC; Ghazani AA; Ghosh R; Green RC; Hart R; Horton C; Johnston JJ; Lebo MS; Milosavljevic A; Ou J; Pak CM; Patel RY; Punj S; Richards CS; Salama J; Strande NT; Yang Y; Plon SE; Biesecker LG; Rehm HL
    Am J Hum Genet; 2016 Jun; 98(6):1067-1076. PubMed ID: 27181684
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.